Can Pancreastatin Predict Survival in Neuroendocrine Tumors?
Serum neurokinin A, chromogranin A, serotonin, and pancreastatin reflect tumor burden in neuroendocrine tumors. We sought to determine whether their levels correlate with survival in surgically-managed small bowel (SBNETs) and pancreatic neuroendocrine tumors (PNETs). Higher pancreastatin levels are significantly associated with worse PFS and OS in SBNETs and PNETs. This effect is independent of age, primary tumor site, and presence of nodal or metastatic disease. Pancreastatin provides valuable prognostic information and identifies surgical patients at high risk of recurrence who could benefit most from novel therapies.
Re: Can Pancreastatin Predict Survival in Neuroendocrine Tumors?
Levels of serum neurokinin A, chromogranin A, serotonin, and pancreastatin have been identified as indicative of tumor burden in neuroendocrine tumors. In our study, we aimed to investigate whether these biomarker levels exhibit a correlation with survival rates in patients with surgically-treated small bowel (SBNETs) and pancreatic neuroendocrine tumors (PNETs). Remarkably, elevated levels of pancreastatin are significantly linked to poorer progression-free survival (PFS) and overall survival (OS) in both SBNETs and PNETs. Notably, this association holds true regardless of factors such as age bad posture issues, primary tumor location, or the presence of nodal or metastatic disease. The insights gained from pancreastatin measurements offer valuable prognostic insight and serve to identify surgical patients who face a heightened risk of recurrence. This information could prove pivotal in directing these high-risk patients towards novel therapeutic interventions that could potentially enhance their outcomes.